Last reviewed · How we verify
Eloralintide and Tirzepatide
Eloralintide and Tirzepatide is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 1 development. Also known as: LY3841136.
At a glance
| Generic name | Eloralintide and Tirzepatide |
|---|---|
| Also known as | LY3841136 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eloralintide and Tirzepatide CI brief — competitive landscape report
- Eloralintide and Tirzepatide updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Eloralintide and Tirzepatide
What is Eloralintide and Tirzepatide?
Eloralintide and Tirzepatide is a Small molecule drug developed by Eli Lilly and Company.
Who makes Eloralintide and Tirzepatide?
Eloralintide and Tirzepatide is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).
Is Eloralintide and Tirzepatide also known as anything else?
Eloralintide and Tirzepatide is also known as LY3841136.
What development phase is Eloralintide and Tirzepatide in?
Eloralintide and Tirzepatide is in Phase 1.
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Also known as: LY3841136
- Compare: Eloralintide and Tirzepatide vs similar drugs
- Pricing: Eloralintide and Tirzepatide cost, discount & access